Atlas Trials

A Study of Gefapixant (AF-219/MK-7264) in Participants With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough (MK-7264-016)

Clinical trial NCT02502097 · COMPLETED

Trial details

NCT number
NCT02502097
Sponsor
Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Idiopathic Pulmonary FibrosisCough
Start date
2015-08-26
Primary completion
2016-07-01
Enrollment
51

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.